explore -WSS

explore

author：knowledge 2025-09-01 06:04:44 - browse：3185

3d rendered medically accurate illustration of the adrenal gland – biotech and pharma coverage from STAT — Adobe

SAN DIEGO — Neurocrine Biosciences announced on Tuesday that an experimental drug for congenital adrenal hyperplasia succeeded in a late-stage trial, bringing the company a step closer to treating patients with a rare and serious set of genetic disorders that alters their ability to produce key hormones.

In the Phase 3 study, known as CAHtalyst, 182 adults were randomly assigned to receive a placebo or crinecerfont, an oral drug Neurocrine developed to lower male sex hormones patients with the disease produce in excess. Researchers found that, compared to those on placebo, participants who took crinecerfont needed a significantly lower dose of the current standard-of-care treatment, glucocorticoids, after 24 weeks of treatment that they did at the study’s start. And about 63% of participants who took crinecerfont were able to lower their dose of glucocorticoids to levels researchers think would be safer for prolonged use, compared to 18% of those on the placebo.

Neurocine, a San Diego biotech focused on treating rare neurological and endocrine diseases, believes the drug could allow people living with congenital adrenal hyperplasia, or CAH, to avoid some of the more serious side effects of glucocorticoids by allowing them to take lower doses. Long-term use of high doses of these drugs can cause patients to gain weight and put them at risk of diabetes, heart disease, and osteoporosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： For BCIs, commercial hurdles may be bigger than scientific ones

explore

WSS

Ionis drug prevents swelling attacks due to hereditary angioedema

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

OTC birth control: A brief history of over the counter pill design

The Pandemic Treaty must support building strong health systems

White House drug shortage group privately met with industry

Verily hires former Apple Health leader as chief scientific officer

hotspot

explore

hotspot

Medicare details structure of new drug price negotiation program

'Ancient DNA,' 23andMe reveal African American ancestries

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Shifting the focus from loneliness to social health

Drug repurposing or repositioning? The language matters

NIH documents show early flaws of $1.6 billion long Covid program

Guidelines to prevent youth baseball injuries need more muscle

The drug industry sees a key ally in the Senate prevail

Guidelines to prevent youth baseball injuries need more muscle

Change Healthcare can notify patients about the breach, HHS says

knowledge

Verily hires former Apple Health leader as chief scientific officer

ASCO: AstraZeneca says CAR

Innovation in antibiotics is ailing. 'Brain drain' may kill it

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

With trial win, GSK could get blood cancer drug back on market

FDA's Pazdur wants cancer trials to range beyond China alone

Wikipedia

explore

hotspot

explore